Menopause Clinical Trials

Find Menopause Clinical Trials Near You

The Impact of Reducose® on Symptoms of Perimenopause and Glycemic Response: a Randomized Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this double-blind, randomized, placebo-controlled trial is to. evaluate daily Reducose® (mulberry leaf extract) supplementation taken with the two largest meals for 12 weeks on improving glycemic response and perimenopausal symptoms in women aged 40-60 years. Glycemic response is measured using Dexcom Stelo continuous glucose monitors during standardized test meals, and menopausal symptoms and sleep/quality-of-life outcomes are assessed using validated surveys administered through the Chloe app in a decentralized U.S. study.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 40
Maximum Age: 60
Healthy Volunteers: t
View:

• Participants assigned female at birth (aged 40-60 years) will be recruited for the study.

• Females ages 40-60 who are weight stable and with a self- reported Body Mass Index (BMI) between 18.5 to 35 kg/m2.

• Willing to maintain their existing dietary and physical activity patterns throughout the study period.

• Have received a medical physical screening (annual physical) within the last 12 months where blood markers for diabetes were taken and results were within the healthy range.

• Self-reported \>40yrs in age and experiencing irregular periods.

• Willing and able to comply with the study protocol.

• Has given voluntary informed consent to participate in the study.

• Not currently using hormone replacement therapy (HRT) and/or \>3months since their last hormone treatment.

• Experiencing menopause symptoms and meets the minimum score of 12/60 on the Greene Climacteric Scale (GCS).

• Own or have constant access to a smart phone and the apple or android app stores and are willing and able to download the Dexcom and Chloe apps and accept their respective privacy policies.

• Willing to practice a reliable method of non-hormonal contraception for the duration of the study.

• In good general health at the time of screening (Investigator discretion).

• Able to read, understand, and provide informed consent in English.

• Able to receive shipment of the product at an address within the United States.

• Able to complete study assessments over the course of up to 12 weeks.

Locations
United States
California
People Science
RECRUITING
Los Angeles
Time Frame
Start Date: 2025-12-12
Estimated Completion Date: 2026-08
Participants
Target number of participants: 120
Treatments
Experimental: Reducose® Mulberry Leaf Extract
Placebo_comparator: Matching Placebo
Related Therapeutic Areas
Sponsors
Leads: Phynova Group Ltd
Collaborators: People Science

This content was sourced from clinicaltrials.gov